Synthetic folic acid supplements are consumed by 50% of US adults. High folic acid intake can result in CpG island hypermethylation. Recent studies suggest high intake may contribute to carcinogenesis particularly in those persons unable to metabolize folic acid efficiently such as persons homozygous for the 19bp deletion polymorphism in the dihydrofolate reductase(DHFR) gene (rs70991108). Homozygotes (19% of US adults) have less efficient conversion of synthetic folic acid into biological folate. Women homozygous for the DHFR19bp deletion (DHFR19bpdel) are at increased risk for having a child with retinoblastoma, a neuro-ectodermally derived early childhood cancer that has served as a model for understanding carcinogenesis. This risk appears elevated among women homozygous for DHFR19bpdel who consumed folic acid containing prenatal supplements in the first trimester. In retinoblastoma, 37% of disease-causing mutations in the CpG-rich gene, RB1, are due to deamination of methylated cytosines in RB1, while an additional 12% are caused by methylation of the RB1 promoter. We hypothesize that these methylation related RB1-inactivating changes may be induced by less functional genetic variations in folate metabolism and excess exposure in early retinal development. Murine models suggest particular sensitivity to folic acid exposure in early neural development. In humans, periods of dietary inadequacy in early gestation are associated with hyper-methylation at meta- stable epialleles. Pilot data from mutation assays and methylation arrays from our ongoing case-series study of newly diagnosed retinoblastoma (mean age 23 months) in Central Mexico, EpiRbMx, suggest that women who have the less efficient DHFR 19bpdel and high folic acid prenatally have higher risk of a child with a methylation related RB1-inactivating mutation or differentially hyper-methylated RB1 promoter directly resulting in tumor formation. Maternal DHFR19bpdel homozygosity combined with high prenatal folic acid intake may lead to RB1 hyper-methylation in developmentally susceptible cells, thereby contributing to carcinogenesis. Based on the results of our pilot data, we propose to use existing samples and data from 337 cases in our ongoing EpiRbMx study (founded in 2003) including pre-treatment measures of mother and child plasma nutrients, diet intake, genotype, and tumors, to test our hypothesis of an association between maternal DHFR 19bpdel and prenatal folic acid exposure (using plasma and intake measures) and 1) methylation related RB1 mutations, specifically in somatic (non-germline) RB1 mutations, and 2) methylation of the RB1 promoter. We will further examine the impact of DHFR and prenatal folic acid exposure on differential methylation in metastable epialleles to document their effect on the developing epigenome. Given the high frequency of RB1 mutations among poor prognosis adult tumors such as small cell lung cancer(54%) or glioblastoma(11%) and the high proportion (19%) of adults with less efficient folic acid metabolism, the potential translational impact of our study is high, as our results can inform public health policy and evaluation of synthetic folic acid exposure.

Public Health Relevance

Prior work in our cohort of children with retinoblastoma suggests that women homozygous for DHFR19bpdel are at increased risk to have a child with retinoblastoma, particularly when taking prenatal folic acid supplements. We will examine how maternal and child DHFR and folic acid intake may be associated with methylation and associated mutations in retinoblastoma tumor DNA. Retinoblastoma offers us a unique model for examining how folic acid may affect carcinogenesis, of particularly significance given that other studies suggest that elevated folic acid intake may contribute to carcinogenesis in breast, colon and lung cancer

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA192662-01A1
Application #
8976578
Study Section
Special Emphasis Panel (ZRG1-PSE-R (90))
Program Officer
Mahabir, Somdat
Project Start
2015-09-07
Project End
2018-08-31
Budget Start
2015-09-07
Budget End
2016-08-31
Support Year
1
Fiscal Year
2015
Total Cost
$666,923
Indirect Cost
$192,796
Name
Columbia University (N.Y.)
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Kamihara, Junne; Ma, Clement; Fuentes Alabi, Soad Linneth et al. (2017) Socioeconomic status and global variations in the incidence of neuroblastoma: call for support of population-based cancer registries in low-middle-income countries. Pediatr Blood Cancer 64:321-323
Castro-Magdonel, Blanca Elena; Orjuela, Manuela; Camacho, Javier et al. (2017) miRNome landscape analysis reveals a 30 miRNA core in retinoblastoma. BMC Cancer 17:458
García-Chequer, A J; Méndez-Tenorio, A; Olguín-Ruiz, G et al. (2016) Overview of recurrent chromosomal losses in retinoblastoma detected by low coverage next generation sequencing. Cancer Genet 209:57-69
Ladas, Elena J; Orjuela, Manuela; Stevenson, Kristen et al. (2016) Dietary intake and childhood leukemia: The Diet and Acute Lymphoblastic Leukemia Treatment (DALLT) cohort study. Nutrition 32:1103-1109.e1
García-Chequer, A J; Méndez-Tenorio, A; Olguín-López, G et al. (2016) Illumina next generation sequencing data and expression microarrays data from retinoblastoma and medulloblastoma tissues. Data Brief 6:908-16